BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 25705679)

  • 1. WHO multidrug therapy for leprosy: epidemiology of default in treatment in Agra district, Uttar Pradesh, India.
    Kumar A; Girdhar A; Chakma JK; Girdhar BK
    Biomed Res Int; 2015; 2015():705804. PubMed ID: 25705679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized controlled trial to compare cure and relapse rate of paucibacillary multidrug therapy with monthly rifampicin, ofloxacin, and minocycline among paucibacillary leprosy patients in Agra District, India.
    Kumar A; Girdhar A; Girdhar BK
    Indian J Dermatol Venereol Leprol; 2015; 81(4):356-62. PubMed ID: 26144850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of multidrug therapy on leprosy in Baroda district (Gujarat).
    Chopra NK; Agarwal JS; Pandya PG
    Indian J Lepr; 1989 Apr; 61(2):179-89. PubMed ID: 2746026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlates of Defaulting from MDT among Leprosy Patients.
    Raju MS; Elkana M; Failbus P; Palla JP; Hembrom UK; Rao PS
    Indian J Lepr; 2016 Sep; 87(4):241-248. PubMed ID: 29762953
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative study of uniform-MDT and WHO MDT in Pauci and Multi bacillary leprosy patients over 24 months of observation.
    Rao PN; Suneetha S; Pratap DV
    Lepr Rev; 2009 Jun; 80(2):143-55. PubMed ID: 19743618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multidrug therapy in leprosy can prevent relapse--a retrospective study.
    Biswas S; Mondal KK
    Indian J Lepr; 2002; 74(4):313-8. PubMed ID: 12624979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidemiological shift in leprosy in a rural district of central India following introduction of multi-drug therapy (April 1986 to March 1992 and April 1992 to March 2002).
    Pandey A; Uddin MJ; Patel R
    Lepr Rev; 2005 Jun; 76(2):112-8. PubMed ID: 16038244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New lesions after MDT in PB and MB leprosy: a report of 28 cases.
    Kar HK; Sharma P
    Indian J Lepr; 2008; 80(3):247-55. PubMed ID: 19432355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Twelve months fixed duration WHO multidrug therapy for multibacillary leprosy: incidence of relapses in Agra field based cohort study.
    Kumar A; Girdhar A; Girdhar BK
    Indian J Med Res; 2013 Oct; 138(4):536-40. PubMed ID: 24434261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A study on non-adherence to MDT among leprosy patients.
    Rao PS
    Indian J Lepr; 2008; 80(2):149-54. PubMed ID: 19425509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies on risk of leprosy relapses in China: relapses after treatment with multidrug therapy.
    Chen XS; Li WZ; Jiang C; Ye GY
    Int J Lepr Other Mycobact Dis; 1999 Dec; 67(4):379-87. PubMed ID: 10700911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A study on the effectiveness and safety of the WHO/MDT regimen in the northeast of Thailand; a prospective study, 1984-1996.
    Dasananjali K; Schreuder PA; Pirayavaraporn C
    Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):28-36. PubMed ID: 9207751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Field evaluation of WHO-MDT of fixed duration at ALERT, Ethiopia: the AMFES project--I. MDT course completion, case-holding and another score for disability grading.
    de Rijk AJ; Gabre S; Byass P; Berhanu T
    Lepr Rev; 1994 Dec; 65(4):305-19. PubMed ID: 7861917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of relapse in leprosy. The Leprosy Unit, WHO.
    Indian J Lepr; 1995; 67(1):13-26. PubMed ID: 7622926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical, bacteriological and histopathological study of 62 referral relapse cases between Jan 2004 and Dec 2009 at the Foundation for Medical Research, Mumbai.
    Shetty VP; Wakade AV; Ghate SD; Pai VV
    Lepr Rev; 2011 Sep; 82(3):235-43. PubMed ID: 22125931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Six months fixed duration multidrug therapy in paucibacillary leprosy: risk of relapse and disability in Agra PB cohort study.
    Kumar A; Girdhar A; Girdhar BK
    BMJ Open; 2012; 2(4):. PubMed ID: 22893667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gender differences in epidemiological factors associated with treatment completion status of leprosy patients in the most hyperendemic district of Nepal.
    Kumar RB; Singhasivanon P; Sherchand JB; Mahaisavariya P; Kaewkungwal J; Peerapakorn S; Mahotarn K
    Southeast Asian J Trop Med Public Health; 2004 Jun; 35(2):334-9. PubMed ID: 15691132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The occurrence of reactions and impairments in leprosy: experience in the leprosy control program of three provinces in northeastern Thailand, 1987-1995 [correction of 1978-1995]. I. Overview of the study.
    Schreuder PA
    Int J Lepr Other Mycobact Dis; 1998 Jun; 66(2):149-58. PubMed ID: 9728447
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A study on the impact of FD-MDT on 200 leprosy patients.
    Vara N; Marfatiya Y
    Indian J Lepr; 2005; 77(3):217-27. PubMed ID: 16353520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relapses among leprosy patients treated with multidrug therapy: experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia; practical difficulties with diagnosing relapses; operational procedures and criteria for diagnosing relapses.
    Becx-Bleumink M
    Int J Lepr Other Mycobact Dis; 1992 Sep; 60(3):421-35. PubMed ID: 1474281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.